Proclara Biosciences
Cambridge
About Proclara Biosciences
NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $115.7M
- Last round: Series Unknown (Nov 2018)
- Website: proclarabio.com
- Phone: 1(617) 714-5468
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/proclara-biosciences-60031 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.